Roberto Pili - Publications

Affiliations: 
Cellular and Molecular Biology State University of New York, Buffalo, Buffalo, NY, United States 
Area:
Cell Biology, Pharmacy

171 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Shen L, Pili R. Tasquinimod targets suppressive myeloid cells in the tumor microenvironment. Oncoimmunology. 8: e1072672. PMID 31646064 DOI: 10.1080/2162402X.2015.1072672  0.36
2019 Elbanna M, Orillion AR, Damayanti NP, Adelaiye-Ogala R, Shen L, Miles KM, Chintala S, Ciamporcero E, Ramakrishnan S, Ku SY, Rex K, Caenepeel S, Coxon A, Pili R. Dual inhibition of angiopoietin-TIE2 and MET alters the tumor microenvironment and prolongs survival in a metastatic model of renal cell carcinoma. Molecular Cancer Therapeutics. PMID 31582532 DOI: 10.1158/1535-7163.MCT-18-1202  0.96
2019 Bunch B, Krishnan N, Greenspan RD, Ramakrishnan S, Attwood K, Yan L, Qi Q, Wang D, Morrison C, Omilian A, Bshara W, Pili R, Trump DL, Johnson C, Woloszynska A. TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC). Cell Cycle (Georgetown, Tex.). 1-12. PMID 31318640 DOI: 10.1080/15384101.2019.1638693  0.96
2018 Orillion AR, Damayanti NP, Shen L, Adelaiye-Ogala R, Affronti HC, Elbanna M, Chintala S, Ciesielski MJ, Fontana L, Kao C, Elzey BD, Ratliff TL, Nelson DE, Smiraglia DJ, Abrams SI, ... Pili R, et al. Dietary protein restriction reprograms tumor associated macrophages and enhances immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30190370 DOI: 10.1158/1078-0432.CCR-18-0980  0.36
2018 Damayanti NP, Budka JA, Khella HWZ, Ferris MW, Ku SY, Kauffman EC, Wood AC, Ahmed K, Chintala VN, Adelaiye-Ogala R, Elbanna M, Orillion AR, Chintala S, Kao C, Linehan WM, ... ... Pili R, et al. Therapeutic targeting of TFE3/IRS-1/PI3K/mTOR axis in translocation renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30061365 DOI: 10.1158/1078-0432.CCR-18-0269  0.6
2018 Adelaiye-Ogala R, Damayanti NP, Orillion AR, Arisa S, Chintala S, Titus MA, Kao C, Pili R. Therapeutic targeting of sunitinib-induced AR phosphorylation in renal cell carcinoma. Cancer Research. PMID 29572225 DOI: 10.1158/0008-5472.CAN-17-3386  0.32
2017 Ramakrishnan S, Hu Q, Krishnan N, Wang D, Smit E, Granger V, Rak M, Attwood K, Johnson C, Morrison C, Pili R, Chatta G, Guru K, Gueron G, McNally L, et al. Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer. Cell Death & Disease. 8: 3217. PMID 29242529 DOI: 10.1038/s41419-017-0024-5  0.96
2017 Adelaiye-Ogala R, Budka J, Damayanti NP, Arrington J, Ferris MW, Hsu CC, Chintala S, Orillion AR, Miles KM, Shen L, Elbanna M, Ciamporcero E, Arisa S, Pettazzoni P, Draetta GF, ... ... Pili R, et al. EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming. Cancer Research. PMID 28978636 DOI: 10.1158/0008-5472.CAN-17-0899  0.36
2017 Pili R, Quinn DI, Hammers H, Monk JP, George S, Dorff T, Olencki T, Shen L, Orillion AR, Lamonica D, Fragomeni RAS, Szabo Z, Hutson AD, Groman A, Perkins SM, et al. Immunomodulation by entinostat in renal cell carcinoma patients receiving high dose interleukin 2: a multicenter, single-arm, phase 1/2 trial (NCI-CTEP#7870). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28939740 DOI: 10.1158/1078-0432.CCR-17-1178  0.36
2017 Wentink MQ, Verheul HMW, Pal SK, George S, Voortman J, Danchaivijitr P, Adelaiye R, Poslinski D, Groman A, Hutson A, Pili R. Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma. Clinical Genitourinary Cancer. PMID 28781191 DOI: 10.1016/j.clgc.2017.07.004  0.84
2017 Orillion A, Hashimoto A, Damayanti NP, Shen L, Adelaiye-Ogala R, Arisa S, Chintala S, Ordentlich P, Kao C, Elzey B, Gabrilovich D, Pili R. Entinostat neutralizes myeloid derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28698201 DOI: 10.1158/1078-0432.CCR-17-0741  0.36
2017 Pili R, Liu G, Chintala S, Verheul H, Rehman S, Attwood K, Lodge MA, Wahl R, Martin JI, Miles KM, Paesante S, Adelaiye R, Godoy A, King S, Zwiebel J, et al. Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial. British Journal of Cancer. PMID 28222071 DOI: 10.1038/bjc.2017.33  0.84
2016 Wei L, Chintala S, Ciamporcero E, Ramakrishnan S, Elbanna M, Wang J, Hu Q, Glenn ST, Murakami M, Liu L, Cortes Gomez E, Sun Y, Conroy J, Miles KM, Malathi K, ... ... Pili R, et al. Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts. Oncotarget. PMID 27823983 DOI: 10.18632/oncotarget.13062  0.96
2016 Ramakrishnan S, Ku S, Ciamporcero E, Miles KM, Attwood K, Chintala S, Shen L, Ellis L, Sotomayor P, Swetzig W, Huang R, Conroy D, Orillion A, Das G, Pili R. HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma. Bmc Cancer. 16: 617. PMID 27506904 DOI: 10.1186/s12885-016-2604-7  0.96
2016 Ellis L, Ku S, Li Q, Azabdaftari G, Seliski J, Olson B, Netherby CS, Tang DG, Abrams SI, Goodrich DW, Pili R. Generation of a C57BL/6 MYC-driven mouse model and cell line of prostate cancer. The Prostate. PMID 27225803 DOI: 10.1002/pros.23206  0.96
2016 Petretto DR, Pili R, Gaviano L, Matos López C, Zuddas C. [Active ageing and success: A brief history of conceptual models]. Revista Espanola De Geriatria Y Gerontologia. PMID 27156859 DOI: 10.1016/j.regg.2015.10.003  0.96
2016 Wang J, Papanicolau-Sengos A, Chintala S, Wei L, Liu B, Hu Q, Miles KM, Conroy JM, Glenn ST, Costantini M, Magi-Galluzzi C, Signoretti S, Choueiri T, Gallucci M, Sentinelli S, ... ... Pili R, et al. Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation. Oncotarget. PMID 27144525 DOI: 10.18632/oncotarget.9093  0.96
2016 Shen L, Orillion A, Pili R. Histone deacetylase inhibitors as immunomodulators in cancer therapeutics. Epigenomics. PMID 26950532 DOI: 10.2217/epi.15.118  0.96
2015 Montgomery B, Eisenberger MA, Rettig MB, Chu FM, Pili R, Stephenson J, Vogelzang NJ, Koletsky AJ, Nordquist LT, Edenfield WJ, Mamlouk K, Ferrante KJ, Taplin ME. Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26527750 DOI: 10.1158/1078-0432.CCR-15-1432  0.96
2015 Pokuri VK, Syed JR, Yang Z, Field EP, Cyriac S, Pili R, Levine EG, Azabdaftari G, Trump DL, Guru K, George S. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. Clinical Genitourinary Cancer. PMID 26508364 DOI: 10.1016/j.clgc.2015.09.013  0.6
2015 Lamming DW, Cummings NE, Rastelli AL, Gao F, Cava E, Bertozzi B, Spelta F, Pili R, Fontana L. Restriction of dietary protein decreases mTORC1 in tumors and somatic tissues of a tumor-bearing mouse xenograft model. Oncotarget. PMID 26378060 DOI: 10.18632/oncotarget.5180  0.96
2015 Kalmuk J, Folaron M, Buchinger J, Pili R, Seshadri M. Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer. Oncotarget. 6: 24376-92. PMID 26203773 DOI: 10.18632/oncotarget.4463  0.96
2015 Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L, Adelaiye R, Miles KM, Ullio C, Pizzimenti S, Daga M, Azabdaftari G, Attwood K, Johnson C, Zhang J, ... ... Pili R, et al. YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene. PMID 26119935 DOI: 10.1038/onc.2015.219  0.96
2015 Weiss A, Ding X, van Beijnum JR, Wong I, Wong TJ, Berndsen RH, Dormond O, Dallinga M, Shen L, Schlingemann RO, Pili R, Ho CM, Dyson PJ, van den Bergh H, Griffioen AW, et al. Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer. Angiogenesis. 18: 233-44. PMID 25824484 DOI: 10.1007/s10456-015-9462-9  0.96
2015 Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, ... ... Pili R, et al. Kidney cancer, version 3.2015. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 151-9. PMID 25691606  0.96
2015 Kirk JS, Schaarschuch K, Dalimov Z, Lasorsa E, Ku S, Ramakrishnan S, Hu Q, Azabdaftari G, Wang J, Pili R, Ellis L. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer. Oncotarget. 6: 3136-46. PMID 25605014  0.96
2015 Adelaiye R, Ciamporcero E, Miles KM, Sotomayor P, Bard J, Tsompana M, Conroy D, Shen L, Ramakrishnan S, Ku SY, Orillion A, Prey J, Fetterly G, Buck M, Chintala S, ... ... Pili R, et al. Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. Molecular Cancer Therapeutics. 14: 513-22. PMID 25519701 DOI: 10.1158/1535-7163.MCT-14-0208  0.96
2015 Ciamporcero E, Miles KM, Adelaiye R, Ramakrishnan S, Shen L, Ku S, Pizzimenti S, Sennino B, Barrera G, Pili R. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Molecular Cancer Therapeutics. 14: 101-10. PMID 25381264 DOI: 10.1158/1535-7163.MCT-14-0094  0.96
2015 Shen L, Sundstedt A, Ciesielski M, Miles KM, Celander M, Adelaiye R, Orillion A, Ciamporcero E, Ramakrishnan S, Ellis L, Fenstermaker R, Abrams SI, Eriksson H, Leanderson T, Olsson A, ... Pili R, et al. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunology Research. 3: 136-48. PMID 25370534 DOI: 10.1158/2326-6066.CIR-14-0036  0.96
2015 Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, ... ... Pili R, et al. Testicular cancer, version 2.2015: Clinical pactice guidelines in oncology Jnccn Journal of the National Comprehensive Cancer Network. 13: 772-799. DOI: 10.1007/978-3-642-54859-8_57  0.96
2015 Kirk JS, Schaarschuch K, Dalimov Z, Lasorsa E, Ku SY, Ramakrishnan S, Hu Q, Azabdaftari G, Wang J, Pili R, Ellis L. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer Oncotarget. 6: 3136-3146.  0.96
2014 Gotink KJ, Broxterman HJ, Honeywell RJ, Dekker H, de Haas RR, Miles KM, Adelaiye R, Griffioen AW, Peters GJ, Pili R, Verheul HM. Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature. Oncoscience. 1: 844-53. PMID 25621299 DOI: 10.18632/oncoscience.106  0.96
2014 Ellis L, Lehet K, Ku S, Azabdaftari G, Pili R. Generation of a syngeneic orthotopic transplant model of prostate cancer metastasis. Oncoscience. 1: 609-613. PMID 25485289 DOI: 10.18632/oncoscience.88  0.96
2014 Miles KM, Seshadri M, Ciamporcero E, Adelaiye R, Gillard B, Sotomayor P, Attwood K, Shen L, Conroy D, Kuhnert F, Lalani AS, Thurston G, Pili R. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts. Plos One. 9: e112371. PMID 25393540 DOI: 10.1371/journal.pone.0112371  0.96
2014 Armstrong AJ, Kaboteh R, Carducci MA, Damber JE, Stadler WM, Hansen M, Edenbrandt L, Forsberg G, Nordle Ö, Pili R, Morris MJ. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). Urologic Oncology. 32: 1308-16. PMID 25240761 DOI: 10.1016/j.urolonc.2014.08.006  0.96
2014 Pili R, Carducci M, Brown P, Hurwitz H. An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer. Investigational New Drugs. 32: 1258-68. PMID 25152243 DOI: 10.1007/s10637-014-0147-9  0.96
2014 Ku S, Lasorsa E, Adelaiye R, Ramakrishnan S, Ellis L, Pili R. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer. Plos One. 9: e103680. PMID 25072314 DOI: 10.1371/journal.pone.0103680  0.96
2014 Kato Y, Yoshino I, Egusa C, Maeda T, Pili R, Tsuboi R. Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells. Journal of Dermatological Science. 75: 140-7. PMID 24866536 DOI: 10.1016/j.jdermsci.2014.04.014  0.96
2014 Tracz A, Mastri M, Lee CR, Pili R, Ebos JM. Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomy. Journal of Visualized Experiments : Jove. PMID 24836396 DOI: 10.3791/51485  0.96
2014 Hanzly M, Aboumohamed A, Yarlagadda N, Creighton T, Digiorgio L, Fredrick A, Rao G, Mehedint D, George S, Attwood K, Kauffman E, Narashima D, Khushalani NI, Pili R, Schwaab T. High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience. Urology. 83: 1129-34. PMID 24767525 DOI: 10.1016/j.urology.2014.02.005  0.96
2014 Gupta N, Al Ustwani O, Shen L, Pili R. Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer. Oncotargets and Therapy. 7: 223-34. PMID 24600234 DOI: 10.2147/OTT.S53524  0.96
2014 Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, ... ... Pili R, et al. Kidney cancer, version 2.2014. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 175-82. PMID 24586079  0.96
2014 Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, Hammers H, Eisenberger MA, Sinibaldi V, Pili R, Hayat H, Kovel S, Sella A, Boursi B, Weitzen R, et al. Active smokingmay negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treatedwith sunitinib Oncologist. 19: 51-60. PMID 24309979 DOI: 10.1634/theoncologist.2012-0335  0.96
2014 Buck MJ, Raaijmakers LM, Ramakrishnan S, Wang D, Valiyaparambil S, Liu S, Nowak NJ, Pili R. Alterations in chromatin accessibility and DNA methylation in clear cell renal cell carcinoma. Oncogene. 33: 4961-5. PMID 24186201 DOI: 10.1038/onc.2013.455  0.96
2014 Raymond E, Dalgleish A, Damber JE, Smith M, Pili R. Mechanisms of action of tasquinimod on the tumour microenvironment Cancer Chemotherapy and Pharmacology. 73: 1-8. DOI: 10.1007/s00280-013-2321-8  0.96
2013 Fontana L, Adelaiye RM, Rastelli AL, Miles KM, Ciamporcero E, Longo VD, Nguyen H, Vessella R, Pili R. Dietary protein restriction inhibits tumor growth in human xenograft models. Oncotarget. 4: 2451-61. PMID 24353195  0.96
2013 Armstrong AJ, Häggman M, Stadler WM, Gingrich JR, Assikis V, Polikoff J, Damber JE, Belkoff L, Nordle Ö, Forsberg G, Carducci MA, Pili R. Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6891-901. PMID 24255071 DOI: 10.1158/1078-0432.CCR-13-1581  0.96
2013 Ellis L, Ku SY, Ramakrishnan S, Lasorsa E, Azabdaftari G, Godoy A, Pili R. Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer. Oncotarget. 4: 2225-36. PMID 24163230  0.96
2013 Rehman S, Crane A, Din R, Raza SJ, Shi Y, Wilding G, Levine EG, George S, Pili R, Trump DL, Guru KA. Understanding avoidance, refusal, and abandonment of chemotherapy before and after cystectomy for bladder cancer. Urology. 82: 1370-5. PMID 24125689 DOI: 10.1016/j.urology.2013.07.055  0.96
2013 Batty N, Yarlagadda N, Pili R. Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 911-5. PMID 23946170  0.96
2013 Ramakrishnan S, Ellis L, Pili R. Histone modifications: implications in renal cell carcinoma. Epigenomics. 5: 453-62. PMID 23895657 DOI: 10.2217/epi.13.40  0.96
2013 Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, Pitot H, Tan W, Miles KM, Erlichman C, Vaishampayan U. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clinical Genitourinary Cancer. 11: 477-83. PMID 23891158 DOI: 10.1016/j.clgc.2013.05.005  0.96
2013 Ramakrishnan S, Pili R. Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma. Cancer Journal (Sudbury, Mass.). 19: 333-40. PMID 23867515 DOI: 10.1097/PPO.0b013e3182a09e07  0.96
2013 Chatterjee S, Alsaeedi N, Hou J, Bandaru VV, Wu L, Halushka MK, Pili R, Ndikuyeze G, Haughey NJ. Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model. Plos One. 8: e63726. PMID 23671696 DOI: 10.1371/journal.pone.0063726  0.96
2013 George S, Pili R. Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer. Current Oncology Reports. 15: 65-8. PMID 23334511 DOI: 10.1007/s11912-013-0295-7  0.96
2013 Pili R, Kauffman E, Rodriguez R. Cancer of the Kidney Abeloff's Clinical Oncology: Fifth Edition. 1416-1444.e5. DOI: 10.1016/B978-1-4557-2865-7.00082-5  0.96
2012 Shen L, Pili R. Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy. Oncoimmunology. 1: 948-950. PMID 23162767 DOI: 10.4161/onci.20306  0.96
2012 Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, Rosenbaum E, Kovel S, Pili R, Sinibaldi V, Carducci MA, Hammers H, Eisenberger MA, Sella A. Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: Association with outcome and predictive nomogram Oncologist. 17: 1508-1514. PMID 22971522 DOI: 10.1634/theoncologist.2012-0125  0.96
2012 Minelli R, Cavalli R, Ellis L, Pettazzoni P, Trotta F, Ciamporcero E, Barrera G, Fantozzi R, Dianzani C, Pili R. Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 47: 686-94. PMID 22917641 DOI: 10.1016/j.ejps.2012.08.003  0.96
2012 Welti JC, Powles T, Foo S, Gourlaouen M, Preece N, Foster J, Frentzas S, Bird D, Sharpe K, van Weverwijk A, Robertson D, Soffe J, Erler JT, Pili R, Springer CJ, et al. Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis. 15: 623-41. PMID 22843200 DOI: 10.1007/s10456-012-9291-z  0.96
2012 Chintala S, Najrana T, Toth K, Cao S, Durrani FA, Pili R, Rustum YM. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition. Bmc Cancer. 12: 293. PMID 22804960 DOI: 10.1186/1471-2407-12-293  0.96
2012 Tolcher AW, Chi KN, Shore ND, Pili R, Molina A, Acharya M, Kheoh T, Jiao JJ, Gonzalez M, Trinh A, Pankras C, Tran N. Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. 70: 305-13. PMID 22752297 DOI: 10.1007/s00280-012-1916-9  0.96
2012 Ebos JM, Pili R. Mind the gap: potential for rebounds during antiangiogenic treatment breaks. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3719-21. PMID 22679177 DOI: 10.1158/1078-0432.CCR-12-1459  0.96
2012 Morris MJ, Eisenberger MA, Pili R, Denmeade SR, Rathkopf D, Slovin SF, Farrelly J, Chudow JJ, Vincent M, Scher HI, Carducci MA. A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 23: 2714-9. PMID 22553195 DOI: 10.1093/annonc/mds078  0.96
2012 Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, ... ... Pili R, et al. Testicular cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 10: 502-35. PMID 22491049  0.96
2012 Keizman D, Ish-Shalom M, Pili R, Hammers H, Eisenberger MA, Sinibaldi V, Boursi B, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Berger R, Carducci MA. Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma European Journal of Cancer. 48: 1031-1037. PMID 22409947 DOI: 10.1016/j.ejca.2012.02.050  0.96
2012 Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, Shrikant P, Fenstermaker R, Pili R. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. Plos One. 7: e30815. PMID 22303460 DOI: 10.1371/journal.pone.0030815  0.96
2012 Wang ES, Pili R, Seshadri M. Modulation of chemotherapeutic efficacy by vascular disrupting agents: optimizing the sequence and schedule. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 760-1; author reply . PMID 22291088 DOI: 10.1200/JCO.2011.39.3934  0.96
2012 Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, Carducci MA, Rudek MA. Phase i study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours British Journal of Cancer. 106: 77-84. PMID 22134508 DOI: 10.1038/bjc.2011.527  0.96
2012 Ellis L, Shah P, Hammers H, Lehet K, Sotomayor P, Azabdaftari G, Seshadri M, Pili R. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. Molecular Cancer Therapeutics. 11: 383-92. PMID 22084164 DOI: 10.1158/1535-7163.MCT-11-0748  0.96
2012 Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, Carducci MA. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. European Journal of Cancer (Oxford, England : 1990). 48: 202-8. PMID 22018713 DOI: 10.1016/j.ejca.2011.09.001  0.96
2012 Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Pili R. Development of a castrate resistant transplant tumor model of prostate cancer. The Prostate. 72: 587-91. PMID 21796655 DOI: 10.1002/pros.21465  0.96
2012 Bruce JY, Eickhoff J, Pili R, Logan T, Carducci M, Arnott J, Treston A, Wilding G, Liu G. A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate. Investigational New Drugs. 30: 794-802. PMID 21174224 DOI: 10.1007/s10637-010-9618-9  0.96
2012 Ramakrishnan S, Pili R. Epigenetic targeting and histone deacetylase inhibition in RCC Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets. 2147483647: 193-211. DOI: 10.1007/978-1-4614-2400-0_9  0.96
2011 Tamaskar I, Dhillon J, Pili R. Resistance to angiogenesis inhibitors in renal cell carcinoma. Clinical Advances in Hematology & Oncology : H&O. 9: 101-10. PMID 22173604  0.96
2011 Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Miles KM, Wang D, Liu S, Atadja P, Carducci MA, Pili R. Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression. Plos One. 6: e27178. PMID 22087262 DOI: 10.1371/journal.pone.0027178  0.96
2011 Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H, Honeywell RJ, Rudek MA, Beerepoot LV, Musters RJ, Jansen G, Griffioen AW, Assaraf YG, Pili R, Peters GJ, Verheul HM. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7337-46. PMID 21980135 DOI: 10.1158/1078-0432.CCR-11-1667  0.96
2011 Pili R, Häggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A, Nordle O, Forsberg G, Carducci MA, Armstrong AJ. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4022-8. PMID 21931019 DOI: 10.1200/JCO.2011.35.6295  0.96
2011 George S, Pili R, Carducci MA, Kim JJ. Role of immunotherapy for renal cell cancer in 2011. Journal of the National Comprehensive Cancer Network : Jnccn. 9: 1011-8. PMID 21917625  0.96
2011 Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, ... ... Pili R, et al. Kidney cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 9: 960-77. PMID 21917622  0.96
2011 Schwaab T, Pili R. Provenge: combating prostate cancer with a vengeance? Expert Review of Vaccines. 10: 1113-4. PMID 21854304 DOI: 10.1586/erv.11.85  0.96
2011 Pettazzoni P, Ciamporcero E, Medana C, Pizzimenti S, Dal Bello F, Minero VG, Toaldo C, Minelli R, Uchida K, Dianzani MU, Pili R, Barrera G. Nuclear factor erythroid 2-related factor-2 activity controls 4-hydroxynonenal metabolism and activity in prostate cancer cells. Free Radical Biology & Medicine. 51: 1610-8. PMID 21816220 DOI: 10.1016/j.freeradbiomed.2011.07.009  0.96
2011 O'Malley RL, Brewer KA, Hayn MH, Kim HL, Underwood W, Pili R, Schwaab T. Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible? Urology. 78: 595-600. PMID 21777963 DOI: 10.1016/j.urology.2011.03.009  0.96
2011 Keizman D, Huang P, Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, Hammers H, Carducci MA. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. European Journal of Cancer (Oxford, England : 1990). 47: 1955-61. PMID 21600760 DOI: 10.1016/j.ejca.2011.04.019  0.96
2011 Hudes GR, Carducci MA, Choueiri TK, Esper P, Jonasch E, Kumar R, Margolin KA, Michaelson MD, Motzer RJ, Pili R, Roethke S, Srinivas S. NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. Journal of the National Comprehensive Cancer Network : Jnccn. 9: S1-29. PMID 21335444  0.96
2011 Pettazzoni P, Pizzimenti S, Toaldo C, Sotomayor P, Tagliavacca L, Liu S, Wang D, Minelli R, Ellis L, Atadja P, Ciamporcero E, Dianzani MU, Barrera G, Pili R. Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells. Free Radical Biology & Medicine. 50: 313-22. PMID 21078383 DOI: 10.1016/j.freeradbiomed.2010.11.011  0.96
2011 Harrison MR, Hahn NM, Pili R, Oh WK, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Investigational New Drugs. 29: 1465-74. PMID 20499131 DOI: 10.1007/s10637-010-9455-x  0.96
2011 Resta LP, Pili R, Eisenberger MA, Spitz A, King S, Porter J, Franke A, Boinpally R, Carducci MA, Sweeney CJ. A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. Cancer Chemotherapy and Pharmacology. 67: 431-8. PMID 20445979 DOI: 10.1007/s00280-010-1328-7  0.96
2011 George S, Pili R. Bisphosphonates in renal cell carcinoma: Palliation versus antitumor effects Targeted Therapies For Renal Cell Carcinoma. 121-125. DOI: 10.2217/EBO.11.3  0.96
2010 Pili R. Is this a true renaissance for the treatment of prostate cancer? Oncology (Williston Park, N.Y.). 24: 1327-8. PMID 21294477  0.96
2010 Ellis L, Pili R. Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies. Pharmaceuticals (Basel, Switzerland). 3: 2411-2469. PMID 21151768 DOI: 10.3390/ph3082441  0.96
2010 Keizman D, Zahurak M, Sinibaldi V, Carducci M, Denmeade S, Drake C, Pili R, Antonarakis ES, Hudock S, Eisenberger M. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5269-76. PMID 20978144 DOI: 10.1158/1078-0432.CCR-10-1928  0.96
2010 Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, Shah P, Ellis L, Shen L, Paesante S, Dykema K, Furge K, Teh BT, Netto G, Pili R. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Molecular Cancer Therapeutics. 9: 1525-35. PMID 20501804 DOI: 10.1158/1535-7163.MCT-09-1106  0.96
2010 Pili R, Rosenthal MA, Mainwaring PN, Van Hazel G, Srinivas S, Dreicer R, Goel S, Leach J, Wong S, Clingan P. Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2906-14. PMID 20460477 DOI: 10.1158/1078-0432.CCR-09-3026  0.96
2010 Snyder CF, Blackford AL, Brahmer JR, Carducci MA, Pili R, Stearns V, Wolff AC, Dy SM, Wu AW. Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30. Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 19: 837-45. PMID 20340048 DOI: 10.1007/s11136-010-9636-2  0.96
2010 Koskimaki JE, Karagiannis ED, Tang BC, Hammers H, Watkins DN, Pili R, Popel AS. Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model. Bmc Cancer. 10: 29. PMID 20122172 DOI: 10.1186/1471-2407-10-29  0.96
2010 Verheul HM, van Erp K, Homs MY, Yoon GS, van der Groep P, Rogers C, Hansel DE, Netto GJ, Pili R. The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma. Urology. 75: 608-14. PMID 19683801 DOI: 10.1016/j.urology.2009.05.075  0.96
2009 Salumbides BC, Lehet KM, Ndikuyeze G, Pili R. Pre-clinical models of renal carcinoma and their utility in drug development. Current Protocols in Pharmacology / Editorial Board, S.J. Enna (Editor-in-Chief) ... [Et Al.]. Unit 14.13. PMID 22294393 DOI: 10.1002/0471141755.ph1413s47  0.96
2009 Tamaskar I, Pili R. Update on novel agents in renal cell carcinoma. Expert Review of Anticancer Therapy. 9: 1817-27. PMID 19954293 DOI: 10.1586/era.09.157  0.96
2009 Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC, Pili R, Zwiebel J, Scher H, Hussain M. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): Trial results and interleukin-6 analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago phase 2 consortium Cancer. 115: 5541-5549. PMID 19711464 DOI: 10.1002/cncr.24597  0.96
2009 Snyder CF, Garrett-Mayer E, Blackford AL, Brahmer JR, Carducci MA, Pili R, Stearns V, Wolff AC, Dy SM, Wu AW. Concordance of cancer patients' function, symptoms, and supportive care needs. Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 18: 991-8. PMID 19657724 DOI: 10.1007/s11136-009-9519-6  0.96
2009 Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, ... ... Pili R, et al. NCCN clinical practice guidelines in oncology: kidney cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 7: 618-30. PMID 19555584  0.96
2009 Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, ... ... Pili R, et al. NCCN clinical practice guidelines in oncology: testicular cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 7: 672-93. PMID 19555582  0.96
2009 Vaughn DJ, Srinivas S, Stadler WM, Pili R, Petrylak D, Sternberg CN, Smith DC, Ringuette S, De Wit E, Pautret V, George C. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: Results of a large phase 2 study Cancer. 115: 4110-4117. PMID 19536904 DOI: 10.1002/cncr.24460  0.96
2009 Pili R. Recent investigations of histone deacetylase inhibitors in renal cell carcinoma. Clinical Advances in Hematology & Oncology : H&O. 7: 252-4. PMID 19521328  0.96
2009 Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3584-90. PMID 19487381 DOI: 10.1200/JCO.2008.20.1293  0.96
2009 Kolmakova A, Rajesh M, Zang D, Pili R, Chatterjee S. VEGF recruits lactosylceramide to induce endothelial cell adhesion molecule expression and angiogenesis in vitro and in vivo. Glycoconjugate Journal. 26: 547-58. PMID 19219548 DOI: 10.1007/s10719-008-9206-9  0.96
2009 Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Letters. 280: 145-53. PMID 19111391 DOI: 10.1016/j.canlet.2008.11.012  0.96
2008 Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W, Ivy SP, Pili R, Carducci MA, Erlichman C, Liu G. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7940-6. PMID 19047126 DOI: 10.1158/1078-0432.CCR-08-0221  0.96
2008 Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, Dang CV, Liu JO, Semenza GL. Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth Proceedings of the National Academy of Sciences of the United States of America. 105: 19579-19586. PMID 19020076 DOI: 10.1073/pnas.0809763105  0.96
2008 Lodge MA, Jacene HA, Pili R, Wahl RL. Reproducibility of tumor blood flow quantification with 15O-water PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 1620-7. PMID 18832120 DOI: 10.2967/jnumed.108.052076  0.96
2008 Rathkopf D, Carducci MA, Morris MJ, Slovin SF, Eisenberger MA, Pili R, Denmeade SR, Kelsen M, Curley T, Halter M, Collins C, Fleisher M, Heller G, Baker SD, Scher HI. Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2959-65. PMID 18565882 DOI: 10.1200/JCO.2007.15.1928  0.96
2008 Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, Atadja P, Pili R. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 3589-97. PMID 18519793 DOI: 10.1158/1078-0432.CCR-07-4306  0.96
2008 Snyder CF, Garrett-Mayer E, Brahmer JR, Carducci MA, Pili R, Stearns V, Wolff AC, Dy SM, Wu AW. Symptoms, supportive care needs, and function in cancer patients: how are they related? Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 17: 665-77. PMID 18493865 DOI: 10.1007/s11136-008-9331-8  0.96
2008 Siu LL, Pili R, Duran I, Messersmith WA, Chen EX, Sullivan R, MacLean M, King S, Brown S, Reid GK, Li Z, Kalita AM, Laille EJ, Besterman JM, Martell RE, et al. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1940-7. PMID 18421048 DOI: 10.1200/JCO.2007.14.5730  0.96
2008 Li J, Jameson MB, Baguley BC, Pili R, Baker SD. Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2102-10. PMID 18381951 DOI: 10.1158/1078-0432.CCR-07-1475  0.96
2008 Shen L, Pili R. Posttranscription regulation of prostate cancer growth. Cancer Journal (Sudbury, Mass.). 14: 46-53. PMID 18303483 DOI: 10.1097/PPO.0b013e318162108a  0.96
2008 Nguyen QD, Shah SM, Hafiz G, Do DV, Haller JA, Pili R, Zimmer-Galler IE, Janjua K, Symons RC, Campochiaro PA. Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration. American Journal of Ophthalmology. 145: 257-266. PMID 18054887 DOI: 10.1016/j.ajo.2007.09.025  0.96
2007 Verheul HM, Lolkema MP, Qian DZ, Hilkes YH, Liapi E, Akkerman JW, Pili R, Voest EE. Platelets take up the monoclonal antibody bevacizumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5341-7. PMID 17855648 DOI: 10.1158/1078-0432.CCR-07-0847  0.96
2007 Kachhap SK, Faith D, Qian DZ, Shabbeer S, Galloway NL, Pili R, Denmeade SR, DeMarzo AM, Carducci MA. The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin. Plos One. 2: e844. PMID 17786215 DOI: 10.1371/journal.pone.0000844  0.96
2007 Collins C, Carducci MA, Eisenberger MA, Isaacs JT, Partin AW, Pili R, Sinibaldi VJ, Walczak JS, Denmeade SR. Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint. Cancer Biology & Therapy. 6: 1360-7. PMID 17786033  0.96
2007 Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, Salumbides BC, Van Erp K, Schulick R, Pili R. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4538-46. PMID 17671140 DOI: 10.1158/1078-0432.CCR-07-0014  0.96
2007 Verheul HM, Hammers H, van Erp K, Wei Y, Sanni T, Salumbides B, Qian DZ, Yancopoulos GD, Pili R. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4201-8. PMID 17634549 DOI: 10.1158/1078-0432.CCR-06-2553  0.96
2007 Qian DZ, Wei YF, Wang X, Kato Y, Cheng L, Pili R. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models. The Prostate. 67: 1182-93. PMID 17520666 DOI: 10.1002/pros.20611  0.96
2007 Bajaj GK, Zhang Z, Garrett-Mayer E, Drew R, Sinibaldi V, Pili R, Denmeade SR, Carducci MA, Eisenberger MA, DeWeese TL. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology. 69: 526-31. PMID 17382158 DOI: 10.1016/j.urology.2006.12.006  0.96
2007 Verheul HM, Qian DZ, Carducci MA, Pili R. Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. Cancer Chemotherapy and Pharmacology. 60: 329-39. PMID 17256134 DOI: 10.1007/s00280-006-0379-2  0.96
2007 Kato Y, Salumbides BC, Wang XF, Qian DZ, Williams S, Wei Y, Sanni TB, Atadja P, Pili R. Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Molecular Cancer Therapeutics. 6: 70-81. PMID 17237267 DOI: 10.1158/1535-7163.MCT-06-0125  0.96
2007 Zhao M, Rudek MA, Mnasakanyan A, Hartke C, Pili R, Baker SD. A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 43: 784-7. PMID 16971082 DOI: 10.1016/j.jpba.2006.08.006  0.96
2006 Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, Kyprianou N, Björk A, Olsson A, Leanderson T. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. The Prostate. 66: 1768-78. PMID 16955399 DOI: 10.1002/pros.20509  0.96
2006 Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA, Atadja P, Pili R. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Research. 66: 8814-21. PMID 16951198 DOI: 10.1158/0008-5472.CAN-05-4598  0.96
2006 Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4092-9. PMID 16943527 DOI: 10.1200/JCO.2005.05.3447  0.96
2006 Sinibaldi VJ, Elza-Brown K, Schmidt J, Eisenberger MA, Rosenbaum E, Denmeade SR, Pili R, Walczak J, Baker SD, Zahurak M, Carducci MA. Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma American Journal of Clinical Oncology: Cancer Clinical Trials. 29: 395-398. PMID 16891869 DOI: 10.1097/01.coc.0000225411.95479.b4  0.96
2006 Chong CR, Qian DZ, Pan F, Wei Y, Pili R, Sullivan DJ, Liu JO. Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target. Journal of Medicinal Chemistry. 49: 2677-80. PMID 16640327 DOI: 10.1021/jm051225t  0.96
2006 Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 634-42. PMID 16428510 DOI: 10.1158/1078-0432.CCR-05-1132  0.96
2005 Motzer RJ, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pili R, Pohar KS, Redman BG, et al. Kidney cancer. Clinical practice guidelines. Journal of the National Comprehensive Cancer Network : Jnccn. 3: 84-93. PMID 19813325  0.96
2005 Heath EI, Gaskins M, Pitot HC, Pili R, Tan W, Marschke R, Liu G, Hillman D, Sarkar F, Sheng S, Erlichman C, Ivy P. A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clinical Prostate Cancer. 4: 138-41. PMID 16197617  0.96
2005 Link RE, Allaf ME, Pili R, Kavoussi LR. Modeling the cost of management options for stage I nonseminomatous germ cell tumors: a decision tree analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5762-73. PMID 16110033 DOI: 10.1200/JCO.2005.09.308  0.96
2005 Rosenbaum E, Zahurak M, Sinibaldi V, Carducci MA, Pili R, Laufer M, DeWeese TL, Eisenberger MA. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 4437-43. PMID 15958628 DOI: 10.1158/1078-0432.CCR-04-2252  0.96
2005 Wang XF, Qian DZ, Ren M, Kato Y, Wei Y, Zhang L, Fansler Z, Clark D, Nakanishi O, Pili R. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 3535-42. PMID 15867257 DOI: 10.1158/1078-0432.CCR-04-1092  0.96
2005 Lin KS, Luu A, Baidoo KE, Hashemzadeh-Gargari H, Chen MK, Brenneman K, Pili R, Pomper M, Carducci MA, Wagner HN. A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation. Bioconjugate Chemistry. 16: 43-50. PMID 15656574 DOI: 10.1021/bc049820h  0.96
2005 Qian DZ, Ren M, Wei Y, Wang X, Van De Geijn F, Rasmussen C, Nakanishi O, Sacchi N, Pili R. In vivo imaging of retinoic acid receptor β2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells Prostate. 64: 20-28. PMID 15651062 DOI: 10.1002/pros.20209  0.96
2004 Lin KS, Luu A, Baidoo KE, Hashemzadeh-Gargari H, Chen MK, Pili R, Pomper M, Carducci M, Wagner HN. A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier. Bioconjugate Chemistry. 15: 1416-23. PMID 15546210 DOI: 10.1021/bc0498267  0.96
2004 Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pili R. The histone deacetylase inhibitor NVP-LAQ824 Inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 Cancer Research. 64: 6626-6634. PMID 15374977 DOI: 10.1158/0008-5472.CAN-04-0540  0.96
2004 Karp JE, Gojo I, Pili R, Gocke CD, Greer J, Guo C, Qian D, Morris L, Tidwell M, Chen H, Zwiebel J. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3577-85. PMID 15173063 DOI: 10.1158/1078-0432.CCR-03-0627  0.96
2004 Sunkara U, Walczak JR, Summerson L, Rogers T, Eisenberger M, Denmeade S, Pili R, Huff CA, Sinibaldi V, Carducci MA. A Phase II Trial of Temozolomide and IFN-α in Patients with Advanced Renal Cell Carcinoma Journal of Interferon and Cytokine Research. 24: 37-41. PMID 14980083 DOI: 10.1089/107999004772719891  0.96
2003 Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, ... ... Pili R, et al. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Research. 63: 5978-91. PMID 14522925  0.96
2003 Pili R, Donehower RC. Is HIF-1α a valid therapeutic target? Journal of the National Cancer Institute. 95: 498-499. PMID 12671009  0.96
2002 Volpert OV, Pili R, Sikder HA, Nelius T, Zaichuk T, Morris C, Shiflett CB, Devlin MK, Conant K, Alani RM. Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell. 2: 473-83. PMID 12498716 DOI: 10.1016/S1535-6108(02)00209-X  0.96
2002 Sirchia SM, Ren M, Pili R, Sironi E, Somenzi G, Ghidoni R, Toma S, Nicolò G, Sacchi N. Endogenous reactivation of the RARβ2 tumor suppressor gene epigenetically silenced in breast cancer Cancer Research. 62: 2455-2461. PMID 11980632  0.96
2001 Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis Cancer Research. 61: 1477-1485. PMID 11245454  0.96
2001 Khan SR, Mhaka A, Pili R, Isaacs JT. Modified synthesis and antiangiogenic activity of Linomide Bioorganic and Medicinal Chemistry Letters. 11: 451-452. PMID 11229745 DOI: 10.1016/S0960-894X(00)00699-5  0.96
1997 Pili R, Chang J, Muhlhauser J, Crystal RG, Capogrossi MC, Passaniti A. Adenovirus-mediated gene transfer of fibroblast growth factor-1: Angiogenesis and tumorigenicity in nude mice International Journal of Cancer. 73: 258-263. PMID 9335452 DOI: 10.1002/(SICI)1097-0215(19971009)73:2<258::AID-IJC16>3.0.CO;2-B  0.96
1995 Mühlhauser J, Pili R, Merrill MJ, Maeda H, Passaniti A, Crystal RG, Capogrossi MC. In vivo angiogenesis induced by recombinant adenovirus vectors coding either for secreted or nonsecreted forms of acidic fibroblast growth factor. Human Gene Therapy. 6: 1457-65. PMID 8573618 DOI: 10.1089/hum.1995.6.11-1457  0.96
1995 Cirielli C, Riccioni T, Yang C, Pili R, Gloe T, Chang J, Inyaku K, Passaniti A, Capogrossi MC. Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in intro and in vivo International Journal of Cancer. 63: 673-679. PMID 7591284 DOI: 10.1002/ijc.2910630512  0.96
1995 Mühlhauser J, Merrill MJ, Pili R, Maeda H, Bacic M, Bewig B, Passaniti A, Edwards NA, Crystal RG, Capogrossi MC. VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Circulation Research. 77: 1077-86. PMID 7586219  0.96
1995 Pili R, Chang J, Partis RA, Mueller RA, Chrest FJ, Passaniti A. The α-Glucosidase I Inhibitor Castanospermine Alters Endothelial Cell Glycosylation, Prevents Angiogenesis, and Inhibits Tumor Growth Cancer Research. 55: 2920-2926. PMID 7540952  0.96
1994 Ziegelstein RC, Spurgeon HA, Pili R, Passaniti A, Cheng L, Corda S, Lakatta EG, Capogrossi MC. A functional ryanodine-sensitive intracellular Ca2+ store is present in vascular endothelial cells Circulation Research. 74: 151-156. PMID 8261589  0.96
1994 Ziegelstein RC, Corda S, Pili R, Passaniti A, Lefer D, Zweier JL, Fraticelli A, Capogrossi MC. Initial contact and subsequent adhesion of human neutrophils or monocytes to human aortic endothelial cells releases an endothelial intracellular calcium store Circulation. 90: 1899-1907. PMID 7923678  0.96
1994 Pili R, Guo Y, Chang J, Nakanishi H, Martin GR, Passaniti A. Altered angiogenesis underlying age-dependent changes in tumor growth. Journal of the National Cancer Institute. 86: 1303-14. PMID 7520508 DOI: 10.1093/jnci/86.17.1303  0.96
1994 Guo Y, Pili R, Passaniti A. Regulation of prostate-specific antigen gene expression in LNCaP human prostatic carcinoma cells by growth, dihydrotestosterone, and extracellular matrix Prostate. 24: 1-10. PMID 7507237  0.96
1993 Pili R, Corda S, Passaniti A, Ziegelstein RC, Heldman AW, Capogrossi MC. Endothelial cell Ca2+ increases upon tumor cell contact and modulates cell-cell adhesion Journal of Clinical Investigation. 92: 3017-3022. PMID 8254056  0.96
1993 Bartoloni C, Guidi L, Di Giovanni AL, Antico L, Cursi F, Pili R, Tricerri A, Janiri L, Mannelli P, Pariante C, Menini E, Carbonin P, Gambassi G. Psychological status, life and social conditions: A study in a population of institutionalized elderly people International Journal of Geriatric Psychiatry. 8: 419-426. DOI: 10.1002/gps.930080509  0.96
1993 Pili R, Ziegelstein RC, Passaniti A, Capogrossi MC. Endothelial cell Ca2+ is increased by melanoma cell adhesion Clinical Chemistry and Enzymology Communications. 6: 79-83.  0.96
1992 Bartoloni C, Guidi L, Tricerri A, Patriarca F, Pili R, Cursi F, Canetta M, Cappelli A, Vangeli M, Salvati F, Gambassi G. Latent coagulation disorders evaluated by the assay of plasma thrombin-antithrombin III complexes in a large series of 'solid tumours' Oncology (Switzerland). 49: 426-430. PMID 1465280 DOI: 10.1159/000227086  0.96
1992 Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, Pauly RR, Grant DS, Martin GR. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Laboratory Investigation; a Journal of Technical Methods and Pathology. 67: 519-28. PMID 1279270  0.96
1991 Guidi L, Bartoloni C, Pellicanò P, Cappelli A, Cursi F, Pili R, Tricerri A, Patriarca F, Gambassi G. Evaluation of latent changes in blood coagulation by the determination of plasma thrombin-antithrombin complex in gastrointestinal neoplasms Clinica Terapeutica. 136: 367-373. PMID 1828201  0.96
1991 Bartoloni C, Guidi L, Antico L, Pariante CM, Di Giovanni A, Pili R, Cursi F, Tricerri A, Tempesta E, Frasca D. Psychological status and immunological parameters of institutionalized aged Panminerva Medica. 33: 164-169. PMID 1771101  0.96
1991 Guidi L, Bartoloni C, Frasca D, Antico L, Pili R, Cursi F, Tempesta E, Rumi C, Menini E, Carbonin P, Doria G, Gambassi G. Impairment of lymphocyte activities in depressed aged subjects Mechanisms of Ageing and Development. 60: 13-24. PMID 1745061 DOI: 10.1016/0047-6374(91)90105-9  0.96
1991 Bartoloni C, Guidi L, Frasca D, Antico L, Pili R, Cursi F, Di Giovanni A, Rumi C, Menini E, Carbonin P, Doria G, Gambassi G. Immune parameters in a populatio of institutionalized elderly subjects: influence of depressive disorders and endocrinological correlations Mechanisms of Ageing and Development. 60: 1-12. PMID 1745060 DOI: 10.1016/0047-6374(91)90104-8  0.96
1990 Bartoloni C, Guidi L, Antico L, Pili R, Cursi F, Carbonin P, Gambassi G, Rumi C, Di Giovanni A, Menichella G, Menini E, Doria DFG, Doria G. Psychological status of institutionalized aged: Influences on immune parameters and endocrinological correlates International Journal of Neuroscience. 51: 279-281. PMID 2279886 DOI: 10.3109/00207459008999720  0.96
1987 Bartoloni C, Guidi L, Pili R, Lewis ZA, Tricerri A, Cursi F, Gentiioni N, Cortesi E, Gambassi G. Assay, isolation and characterization of circulating immune complexes from serum of gastrointestinal cancer, stage iii and iv melanoma and chronic inflammatory bowel disease patients Oncology (Switzerland). 50: 27-34. DOI: 10.1159/000227143  0.96
Show low-probability matches.